Maria Borell

Maria Borrell has a daughter who was diagnosed with Collagen VI Muscular Dystrophy at the age of 3. She is also a senior investigator in the cardiovascular field in Barcelona. Prior appointments include a postdoctoral position the results of which led to a Phase II clinical trial in French Huntington Disease patients. She has also worked in the identification of drugs for cardiovascular diseases in Germany and in the United States. She is an active member of prestigious national and international societies in cardiology. She has been collaborating with EURORDIS for several years now and has participated in several Meetings and Scope actions to Strengthen Collaborations for Operating Pharmacovigilance in Europe. She was also involved in the PARADIGM Program (Patients Active in Research and Dialogues for an Improved Generation of Medicines) that allows structured patient engagement throughout three key decisionmaking points of the development of medicinal products: the research priority setting; the design of clinical trials and the early dialogues with regulators from the different European countries. She is an active member of ASEM (Spanish Muscular Association) and Fundació Noelia (Col VI MD association).

Organisation

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern